These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2568770)

  • 21. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
    Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
    Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody.
    Yun YS; Hargrove ME; Ting CC
    J Immunol; 1988 Aug; 141(4):1390-7. PubMed ID: 3260924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
    J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
    Mulé JJ; Yang JC; Afreniere RL; Shu SY; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):285-94. PubMed ID: 3108401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
    Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
    J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo interaction between murine fibrosarcoma cells and natural killer cells.
    Laybourn KA; Hiserodt JC; Abruzzo LV; Varani J
    Cancer Res; 1986 Jul; 46(7):3407-12. PubMed ID: 2939945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant interleukin 2 allows the differentiation of Thy 1.2+ LAK cells from nude mouse spleen cells.
    Nishimura T; Yagi H; Uchiyama Y; Hashimoto Y
    Immunol Lett; 1986 Mar; 12(2-3):77-82. PubMed ID: 2873098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Purification and target cell range of in vivo elicited blast natural killer cells.
    Biron CA; Pedersen KF; Welsh RM
    J Immunol; 1986 Jul; 137(2):463-71. PubMed ID: 3722814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
    Vujanovic NL; Herberman RB; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generation of lymphokine-activated killer (LAK) cells from tumor-infiltrating lymphocytes.
    Nishimura T; Yagi H; Uchiyama Y; Hashimoto Y
    Cell Immunol; 1986 Jun; 100(1):149-57. PubMed ID: 2874890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo.
    Yoshioka T; Sato S; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1986 Aug; 77(8):825-32. PubMed ID: 3093429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity.
    Ting CC; Hargrove ME; Yun YS
    J Immunol; 1988 Aug; 141(3):741-8. PubMed ID: 3260909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
    Tilden AB; Itoh K; Balch CM
    J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymphokine-induced cytotoxicity: characterization of effectors, precursors, and regulatory ancillary cells.
    Ting CC; Yang SS; Hargrove ME
    Cancer Res; 1986 Feb; 46(2):513-8. PubMed ID: 3079663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
    Gregg EO; Gregg IC; Green I
    Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.
    Hinuma S; Naruo K; Ootsu K; Houkan T; Shiho O; Tsukamoto K
    Immunology; 1987 Feb; 60(2):173-9. PubMed ID: 3493209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymphokine-activated killer cells are generated before classical cytotoxic T lymphocytes after bone marrow transplantation in mice.
    Merluzzi VJ; Savage DM; Smith MD; Last-Barney K; Mertelsmann R; Moore MA; Welte K
    J Immunol; 1985 Sep; 135(3):1702-6. PubMed ID: 3894518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo requirement for asialo GM1 and Thy1 positive leukocytes for antitumor effect of rIL-2 +/- rIFN-gamma.
    Silagi S; Dutkowski R; Schaefer A
    Anticancer Res; 1988; 8(6):1265-9. PubMed ID: 2905882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
    Butler LD; Browne CP; Layman NK; Riedl P; Tang J; Marder P; DeLong D; Manetta J; Bobbitt L; Strnad J
    Cancer Res; 1988 Nov; 48(21):6081-9. PubMed ID: 3048654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymphokine-activated killer cells in mouse bone marrow chimaeras. The relationship to natural killer cells and to alloreactive cytotoxic T cells.
    Sihvola M
    Scand J Immunol; 1985 Nov; 22(5):479-88. PubMed ID: 2867599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.